Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp.

October 08, 2010 08:00 ET

Stem Cell Therapeutics Receives FDA End of Phase II Meeting Date

CALGARY, ALBERTA--(Marketwire - Oct. 8, 2010) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT" or the "Company") wishes to announce that a requested end of Phase II meeting has been reviewed by FDA and a meeting date has been set for December 20, 2010.

Dr. Allen Davidoff, Vice President, Product Development of SCT stated "The Company looks forward to advancing discussions with the FDA regarding the NTx®-265 programs. We anticipate that the meeting will focus on a review of the positive safety data generated to-date in administering NTx®-265, overall analysis of the clinical efficacy data and the encouraging subgroup analysis of the REGENESIS-LED trial. Importantly we will be exploring the design requirements of pivotal trials for NTx®-265 in acute ischemic stroke."

As stated previously, the Company continues to advance as a biotech company considering a range of options, with management focusing its efforts on pursuing the end-of-Phase II meeting with the FDA for the NTx®-265 stroke therapy, developing a similar regimen for traumatic brain injury (TBI) while reviewing alternatives for pursuing multiple sclerosis ("MS") as well as various other opportunities.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

For further information on Stem Cell Therapeutics Corp., visit

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information